Kellogg, Hansen, Todd, Figel & Frederick

Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C. is a distinguished litigation boutique headquartered in Washington, D.C., recognized for its expertise in complex, high-stakes disputes. Founded in 1993, the firm operates from a single office and employs over 100 attorneys. It consistently ranks among the nation's elite, including being named to the Vault Law 100 (#70) and recognized as a top-tier firm for Litigation Specialty (#2), and a finalist for Commercial Litigation (Boutique) Law Firm of the Year by Chambers USA. Chambers USA also ranks Kellogg Hansen highly for General Commercial Litigation, Appellate Law, and Telecommunications.

The firm's patent litigation practice spans a broad range of technologies, with particular strength in pharmaceuticals and biotechnology, especially Biologics Price Competition and Innovation Act (BPCIA) disputes concerning biosimilars. Their experience also extends to internet and computer-related technologies, including voice and video streaming, content delivery networks, optical disc drives, and display technology. While the firm represents both patent holders and accused infringers, its recent tracked case activity shows a notable preference for representing plaintiffs, with five out of six tracked cases appearing on the plaintiff side.

Kellogg Hansen has been prominent in significant pharmaceutical patent litigation for Regeneron Pharmaceuticals, Inc., including multiple cases related to its EYLEA® (aflibercept) product. The firm represented Regeneron in disputes against biosimilar developers such as Mylan Pharmaceuticals Inc., Formycon AG, and Sandoz Inc. The Regeneron v. Sandoz and Regeneron v. Formycon cases both concluded with settlement agreements allowing the biosimilar products to launch in the fourth quarter of 2026. In the Regeneron v. Mylan matter, after a bench trial that found certain patent claims valid and infringed, the Federal Circuit affirmed Regeneron's 13-patent aflibercept portfolio against multiple biosimilar defendants in March 2025. Other representative patent matters on the firm's website include securing a $58 million jury verdict for Verizon against Vonage in a telecommunications patent case, which later settled for $120 million, and obtaining a $14.5 million jury verdict for Ricoh in an optical disc drive infringement action.

While Kellogg Hansen's IP litigation practice emphasizes high-stakes trial and appellate work, detailed public information regarding a distinct, high-volume PTAB or IPR practice is not readily available. Key partners in the firm's IP litigation practice include Jacob Hartman, who handles complex commercial and intellectual property cases and appears on multiple Regeneron matters. John Thorne, a former Verizon SVP and Deputy General Counsel for Intellectual Property, leads cases for technology companies in patent and antitrust matters. Andrew E. Goldsmith is also a prominent litigator, having served as lead counsel in a Regeneron case and representing clients across various industries, including pharmaceutical and technology companies, in patent disputes. Additionally, name partner Mark C. Hansen is highly regarded for his formidable practice encompassing IP disputes, antitrust, and complex commercial litigation.